December 30, 2019 12:14 PM EST

Wave spotlights ‘positive’ data on Huntington’s drug, but stock takes a beating as Roche, Ionis rival stays in front

John Carroll

Editor & Founder

Wave Life Sciences put the most positive spin possible on a snapshot of data from their Huntington’s disease study, but only managed to scare investors …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Wave spotlights ‘positive’ data on Huntington’s drug, but stock takes a beating as Roche, Ionis rival stays in front

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

A VC-backed genetic testing startup to 'consider' making an offer to buy 23andMe

Lasker Award goes to three scientists who pioneered research behind GLP-1 drugs

Breaking down silos with a new quantitative approach to drug development

Wave spot­lights ‘pos­i­tive’ da­ta on Hunt­ing­ton’s drug, but stock takes a beat­ing as Roche, Io­n­is ri­val stays in front

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Wave spotlights ‘positive’ data on Huntington’s drug, but stock takes a beating as Roche, Ionis rival stays in front